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Background: Sunlight can activate photodynamic therapy (PDT), and this is a proven strategy to reduce pain
caused byconventional PDT treatment, but assessment of this and other alternative low dose rate light sources,
and their eﬃcacy, has not been studied in an objective, controlled pre-clinical setting. This study used three
objective assays to assess the eﬃcacy of diﬀerent PDT treatment regimens, using PpIX ﬂuorescence as a photophysical measure, STAT3 cross-linking as a photochemical measure, and keratinocyte damage as a photobiological measure.
Methods: Nude mouse skin was used along with in vivo measures of photosensitizer ﬂuorescence, keratinocyte
nucleus damage from pathology, and STAT3 cross-linking from Western blot analysis. Light sources compared
included a low ﬂuence rate red LED panel, compact ﬂuorescent bulbs, halogen bulbs and direct sunlight, as
compared to traditional PDT delivery with conventional and fractionated high ﬂuence rate red LED light delivery.
Results: Of the three biomarkers, two had strong correlation to the PpIX-weighted light dose, which is calculated
as the product of the treatment light dose (J/cm2) and the normalized PpIX absorption spectra. Comparison of
STAT3 cross-linking to PpIX-weighted light dose had an R = 0.74, and comparison of keratinocyte nuclear
damage R = 0.70. There was little correlation to PpIX ﬂuorescence. These assays indicate most of the low
ﬂuence rate treatment modalities were as eﬀective as conventional PDT, while fractionated PDT showed the
most damage.
Conclusions: Daylight or artiﬁcial light PDT provides an alternative schedule for delivery of drug-light treatment,
and this pre-clinical assay demonstrated that in vivo assays of damage could be used to objectively predict a
clinical outcome in this altered delivery process.

1. Introduction
Conventional photodynamic therapy (PDT) using 5-aminolaevulinic
acid (ALA) is commonly used to treat actinic keratosis (AK) [1,2], with
some investigational and some approved uses in squamous cell carcinoma (SCC) [3], and basal cell carcinoma (BCC) [4–6]. Despite ALAPDT being highly eﬀective to treat AKs and non-melanoma skin cancers,
patients often report moderate to severe pain associated to the

⁎

treatment [7–10], and this has been viewed as one of the more problematic issues in acceptance of the treatment. The source of pain in
ALA-PDT is believed to be from protoporphyrin IX (PpIX) production or
accumulation in nerve endings [11] which leads to damage during illumination. This pain has been related to the PpIX concentration in AK
lesions [12].
To date, several studies have reported daylight-mediated PDT as
eﬀective as conventional PDT to treat AK lesion grade I with reduced
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pain [13]. Since “daylight PDT” consists in a low rate PDT light delivered by the sun for extended periods of time with either none or low
incubation time of the photosensitizer, then the PpIX is produced at the
same time that it is photobleached away in the treatment process
[14–17]. So, the delivery process of daylight PDT appears eﬀective with
sunlight, however at the same time this process of no incubation time
with continuous irradiation could also be easily achieved with lamps in
a clinical setting, where the light delivery and patient behavior might
be better controlled. The development of this paradigm with low pain
but eﬀective light delivery in a clinical setting could be a successful
conduit for increased use of PDT, if demonstrated to be equally eﬀective
as traditional PDT delivery.
In the present study, we investigated the hypothesis that “daylight
PDT” using diﬀerent light sources could be as eﬀective as conventional
PDT, using the well-established model of normal nude mouse skin
[18,19]. The study used three in vivo biomarkers of PDT treatment
eﬃcacy, including PpIX ﬂuorescence assessed by ﬁberoptic dosimetry
[15,20–22], damage to epidermal keratinocytes assessed by pathology
[23], and induction of STAT3 cross-linking [24–26] as assessed by
molecular analysis of biopsy samples, and examined these in response
to diﬀerent light sources as well as conventional PDT and fractionated
PDT [27].

anaesthetized with isoﬂurane.
Light treatments were given for the diﬀerent light sources, directly
measuring the optical irradiance and time of light delivered to the
surface of the tissue. The spectrum of each source relative to the absorption spectrum of PpIX was used to calculate the PpIX-weighted irradiance, which was the product of the normalized PpIX absorption
spectrum and the treatment light as multiplied wavelength by wavelength and then integrated together [28,29]. This process does not take
into account individual variation in PpIX production, but rather just
estimates an ‘eﬀective’ irradiance related to the light source, which
allows comparison between light sources from the theoretical eﬃciency
of how they should excite PpIX. Details of the measurement systems and
exact calculations are in Supplementary data. Time integrated irradiance was then reported as the delivered light dose.
2.2. Fluorescence dosimetry measurements
Active dosimetry of PpIX was done using optical measurements of
remitted ﬂuorescent intensity were acquired with both 405 nm laser
(blue channel) and 635 nm laser (red channel) excitation. These measurements were corrected with white light reﬂectance measurements,
to correct for attenuation due to individual variation. All optical measurements were collected using a previously reported point-probe dosimetry system and the analysis was carried out by applying an iterative
Monte Carlo-based look-up-table (LUT) ﬁtting algorithm [22]. For
“daylight PDT” groups, the measurements were done (1) prior ALA
administration (Pre-ALA) and (2) after light illumination (Post-PDT).
For the regular PDT group (PDT), measurements were performed at
three time points: (1) prior to ALA (Pre-ALA), (2) immediately before
PDT (Pre-PDT) (data not showed), and (3) after treatment (Post-PDT).
For the fractionated light illumination group (fPDT), the measurements
were performed at ﬁve time points: (1) prior to ALA application (PreALA), (2) before 1st light fraction (Pre-1st PDT), (3) after 1st light
fraction (Post-1st PDT), (4) before 2nd light fraction (Pre-2nd PDT), and
(5) after 2nd light fraction (Post-2nd PDT). All measurements were acquired with the probe gently in contact with the back of the mice,
where the ALA was applied. The post-PDT PpIX ﬂuorescence (PpIX
FLnorm) was normalized by subtracting the average skin auto-ﬂuorescence obtained before ALA application (FLPre − ALA ) from the average
ﬂuorescence obtained post-PDT (or post-2nd PDT, for fPDT group)
(FLPost − PDT ) for each mouse and for both the blue and red excitation
channels.

2. Materials and methods
2.1. PDT treatment
All animal studies were approved by Dartmouth College
Institutional Animal Care and Use Committee (IACUC) and conducted
in accordance with institutional PHS and OLAW guidelines.
Seventy female nude mice were used (Charles River Laboratories,
Wilmington, MA) and separated into 10 animals/group with groups: (1)
untreated control (no ALA, no light), (2) sunlight, (3) halogen, (4)
Compact Fluorescent Light (CFL), (5) red LED, (6) traditional PDT, and
(7) fractionated light PDT (fPDT). Groups 5–7 used the same red
(633 nm) LED panel (Omnilux revive, Sydney, Australia), but group 5
was set at a lower ﬂuence rate. All groups were prescribed a total light
dose of ∼78 J/cm2, except for the sun (107 J/cm2), which could not be
easily controlled. The “eﬀective” light dose was calculated by using a
PpIX-weighted irradiance [28,29] (details in supplementary data).
A volume of 20 μL Levulan® Kerastick® (20% of ALA) solution was
applied topically to the back of each mouse. In the “daylight” groups
(sun, halogen, CFL, and LED), the animals received light immediately
after ALA application for 2.5 h. In the single-illumination group (PDT),
the animals were illuminated after 2.5 h of ALA application. In the fPDT
group, the animals were illuminated twice, ﬁrst after 1.25 h of dark
incubation, and then again at 2.5 h after the initial ALA application
(Fig. 1). The ALA was not reapplied during nor between any illuminations. During “daylight” treatment, the animals were awake for the
duration of the procedure, while during PDT and fPDT, the mice were

PpIX FLnorm (a. u. ) = FLPost − PDT − FLPre − ALA

(1)

2.3. Western blot analysis
The proteins from skin were extracted immediately after light
treatment using RIPA buﬀer containing protease and phosphatase inhibitors and 1 mM of PMSF. The skin was kept cooled by ice for approximately 20 min before electric homogenization, followed by centrifuge for 5 min at 13,000 rpm. The supernatant was transferred to a
clean tube, and this sample volume was frozen at −20 °C. This was
repeated for 5 mice/group.
Protein extracts (50 μg) were brieﬂy heated at 100 °C in βME-containing buﬀer, separated on a polyacrylamide gel (4–15% Criterion™
TGX™, Bio-Rad), and transferred to 0.2 μm PVDF membrane (TransBlot® Turbo™ Mini PVDF Transfer, Bio-Rad). On all gels, reference
protein markers for molecular size detection (Precision Plus Protein
Standards Kaleidoscope, Bio-Rad, #161-0375) were included. Nonspeciﬁc interactions were blocked by incubating the membranes with
0.1% Tween 20, 5% powder milk in PBS for 1 h at room temperature.
Membranes reacted overnight at 4 °C with primary antibodies (antiSTAT3 C-20, Santa Cruz, 1:500; anti-β-actin N-21, Santa Cruz, 1:500).
Detection of the immune complexes were performed using a ﬂuorescent
secondary antibody, 1:15,000 (IRDye® 800CW Goat anti-Rabbit IgG, LI-

Fig. 1. Schematic of the diﬀerent PDT regimens is shown with light delivery shown by the
red lines, relative to the time of application of ALA to the skin (left side).
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(2)

0.0083 ±
0.0042
0.0078 ±
0.0073
0.0054 ±
0.0031
0.0087 ±
0.0035
0.010 ±
0.0039
0.0088 ±
0.0036

form I
× 100
monomeric STAT 3

FLPre-ALA
(red
channel)
(mean ±
SD)

STAT 3 cross − links (% form I ) =

FLPost-PDT
(red
channel)
(mean ±
SD)

COR Biosciences). Membranes were then scanned on the Odyssey CLx
Infrared System (LI-COR Biosciences) in 800 nm channel. The quantiﬁcation of each band was determined using the Image Studio Lite
Software (LI-COR Biosciences). The relative amount of STAT3 crosslinking was expressed by the percentage conversion of monomeric
STAT3 into the dimer form I [25]:

0.10 ±
0.061
0.26 ±
0.20
0.15 ±
0.078
0.16 ±
0.055
0.11 ±
0.061
0.046 ±
0.035
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0.0036 ±
0.0017
0.0042 ±
0.0017
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0.0011
8.6

Total light
Dose (J/
cm2)

Halogen

To evaluate if there was photoactivation and destruction of the
photosensitizer after “daylight PDT”, the post-PDT PpIX ﬂuorescence
(PpIX FLnorm) in response to either blue or red excitation channel was
determined and the results compared with “conventional” (single
scheme or fractionated) PDT. Fig. 2 shows that all treatments were
eﬀective in promoting no accumulation of PpIX, with each scheme of
treatment used varying slightly in eﬀect. There are some statistical

350–800

3.2. in vivo measurement of PpIX ﬂuorescence

Sun

While care was taken to match the total light dose (J/cm2) between
groups, the PpIX-weighted light dose, calculated as the product of the
normalized PpIX absorption and the time-integrated treatment light
spectra, presented signiﬁcant variability due to diﬀerences in excitation
spectra (Table 1).

Irradiance
(mW/cm2)

3.1. Total dose vs. PpIX-weighted, “eﬀective” dose

Measured
Wavelength
Range (nm)

3. Results

Light
Source

Table 1
A comparison of the unweighted and PpIX-weighted irradiance and dose for each light source.

PpIXweighted
Irradiance
(mW/cm2)

Statistical analysis was performed with the normality of the distribution evaluated according to the Shapiro-Wilk’s test. For the analysis of diﬀerence between normal distributions, a parametric Student’s
t-test was performed. A non-parametric Mann-Whitney was used to
compare groups with non-normal distributions. Linear regression was
used to test correlation between STAT3 cross-linking, damage to epidermal keratinocytes, PpIX ﬂuorescence, and the PpIX-weighted spectrum; it was reported as Pearson product correlation coeﬃcient (R). Pvalue < 0.05 was considered statistically signiﬁcant. Variables shown
in ﬁgures with diﬀerent overhead letters represent statistically signiﬁcant diﬀerences. All statistical analyses were performed in
OriginPro®8 (OriginLab, Wellesley Hills, MA, USA), with the exception
of the linear regression tests which were done in Python (Version 3.4.3,
SciPy package version 0.19.0).

107

2.5. Statistical analysis

11.9

PpIXweighted
light Dose
(J/cm2)

FLPre-ALA
(blue
channel)
(mean ±
SD)

FLPost-PDT
(blue
channel)
(mean ±
SD)

At 24 h post treatment, the skin was excised, samples ﬁxed overnight in 4% neutral buﬀered formaldehyde, and then routinely processed and embedded in paraﬃn for sectioning into 4 μm thickness and
H & E staining. These sections were scanned on a 20 × objective microscope, and 2 sections per slide were chosen at random to be digitally
scanned for analysis. PDT induced damage was assayed manually by
visually counting nuclei. The majority of the morphological abnormalities was observed in the epidermis, so for simplicity and consistency
the dermis was excluded. Other exclusion criteria were cells surrounding hair follicles and melanocytes because of their irregular frequency of appearance in the scanned sections.
To quantify damage, all keratinocytes appearing in the epidermis
were counted and classiﬁed as either normal or aberrant. Nuclei were
considered aberrant if they appeared pyknotic (dark and condensed
chromatin), hyper eosinophilic (increased pink cytoplasm), shrunken,
fragmented, or washed out. To normalize, the number of aberrant cells
was simply rationed over the total number of cells counted per section.

0.041 ±
0.021
0.11 ± 0.074
0.045 ±
0.019
0.081 ±
0.027
0.067 ±
0.048
0.028 ±
0.017

2.4. H & E staining and microscope analysis
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Fig. 2. Normalized post-PDT PpIX ﬂuorescence, PpIX FLnorm, measured in response to both blue (i) and red (ii) excitation channel,
showing high PpIX activated photobleaching in all treatment groups.
Relative oxygen saturation (iii) and relative BVF (iv) estimates were
determined by white light spectroscopy of the skin with the dosimeter
probe. Letters shared indicate no signiﬁcant diﬀerence.

the most damage, followed by halogen. There was no statistical difference when comparing sunlight, halogen, or CFL with PDT. Almost
normal appearing, with occasional classic (apoptotic) sunburnt cells
were seen for low ﬂuence rate red LED.

diﬀerences between individual treatment groups, but overall daylight
PDT and conventional PDT were similar in their capacity to photoactivate PpIX.
As expected, there was a replenishment of PpIX during the dark
interval between 1st and 2nd scheme of illumination from fPDT group
(data shown in Fig. S4). No signiﬁcant diﬀerence was observed for either relative oxygen saturation or relative blood volume fractionation
(BVF) between treatment groups (Fig. 2).

3.5. Biometric assays correlation with PpIX-weighted, eﬀective light dose
In order to evaluate the eﬃcacy of the bioassays previously described, we compared the PpIX-weighted light dose of each treatment
group to the quantitative assessment of each assay (Fig. 5). There was
little correlation of PpIX ﬂuorescence to the eﬀective light dose
(R = −0.46 [red ex.], −0.37 [blue ex.], data not shown), but signiﬁcant linear correlations to both STAT3 cross-linking (R = 0.74) and
keratinocyte damage (R = 0.70).

3.3. STAT3 protein cross-linking assay
The inﬂuence of either daylight PDT or conventional PDT (PDT and
fPDT) on STAT3 cross-linking was evaluated by measuring the percentage of STAT3 monomer conversion into form I (Fig. 3). The data
showed that all regimens of PDT induced cross-linking of STAT3 relative to the control group (P-value < 0.05); however, there was no
signiﬁcant diﬀerence between “daylight PDT” and conventional PDT
(P-value > 0.05). The results also show that the conversion of STAT3
monomer in form I was highest in mice that received fPDT.

4. Discussion
In this study, the potential implementations of low dose rate or
“daylight PDT” were further investigated as compared to traditional
PDT delivery or fractionated PDT. The “daylight PDT” is here deﬁned as
low-irradiance PDT light dose delivered by the sun, or artiﬁcial lamps,
immediately after application of ALA to the skin [30,31]. This has been
reported in many studies to be a low-pain methodology of delivery
[32], which could lead to wider adoption of PDT as a self-delivered
treatment. This activity produced the motivation for the central hypothesis of this study, which was that the use of diﬀerent low-irradiance
light sources could produce skin damage equally as eﬃciently as

3.4. Evaluation of damage to keratinocytes caused by diﬀerent treatment
regimens
Fig. 4 presents the damage to epidermal keratinocytes as a result of
“daylight PDT” or conventional PDT. Its quantiﬁcation showed a more
pronounced damage in upper epidermis caused by fPDT. Among
“daylight PDT” groups, sun and CFL were the treatments that caused

Fig. 3. Left: Representative Western blot showing STAT3 cross-linking
after ALA-PDT treatment. Right: Quantitative eﬀect of “daylight PDT”
and conventional PDT on STAT3 cross-linking (% of monomer conversion into form I). The values for individual mice were plotted
(n = 5 mice/group). Distinct letters mean statistical diﬀerence.
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Fig. 4. Histological panel of PDT damage localized to the epidermis, representative of the group. Arrows indicate apoptotic cells; arrowheads indicate regions of necrosis. (i) Control; (ii)
Natural sunlight; (iii) Halogen; (iv) CFL; (v) Red LED; (vi) PDT; (vii) fPDT. Scale bar (50 μm) is representative of all images. Diﬀerent letters above the box plots mean signiﬁcant
diﬀerences.

In terms of a more direct biological damage assay, inactivation of
STAT3, a pro-cancer mediator, has been associated with PDT eﬃcacy.
Previous studies have shown that the formation of STAT3 cross-linking
is dependent on the amount of photosensitizer, delivered light dose,
and, light ﬂuence rate [25,26,35]. In a study performed by Rohrbach
et al. [35], low light ﬂuence rate HPPH-PDT induced higher STAT3
cross-linking in a head and neck tumor model. The authors correlated
their results with the vascular shutdown caused in the beginning of the
treatment with high light ﬂuence rate, limiting the oxygen available to
promote the photoreaction [35,36].
A signiﬁcant increase in STAT3 cross-linking was seen in the fractionated PDT group (Fig. 3). This result is consistent with previous
ﬁndings due to the dark interval between fractions during which
oxygen and PpIX can be replenished [21,37–39]. There were no signiﬁcant diﬀerences observed between “daylight” PDT treatment groups
and conventional, single scheme PDT, although all groups were signiﬁcantly diﬀerent from control. There was, however, a PpIX-weighted
light-dose-dependent trend that can be seen in Fig. 5, suggesting that
STAT3 cross-linking could be a sensitive predictor of PDT damage.
Future studies are warranted to investigate the high variability we
observed in our limited sample size.
In order to use a more conventional assay of PDT eﬀect, pathology
stained H & E images were used to quantify the keratinocyte damage,
assayed 1 day after PDT, comparing the sun and lamp groups to “conventional” PDT. As shown in Fig. 4, the damage was similar for all
groups, except for the red LED low ﬂuence rate treatment, which could
be explained by having received the lowest PpIX-weighted light dose
(Table 1). Similar to the STAT3 assay, damage to keratinocyte had a
strong linear correlation to the PpIX-weighted light dose, and should be

conventional or fractionated light PDT. The treatment cohorts used
diﬀerent light sources (including natural sunlight, CFL, halogen, and
red LED) with a low ﬂuence rate delivery, matching the clinical paradigm used for 2.5 h, and the results were evaluated for PpIX ﬂuorescence, cross-linking of STAT3, and damage to epidermal keratinocytes
as a predictor of PDT response. These assays were tested in this mouse
model, because each is a self-calibrated assessment of the skin which
can be applied to clinical trials, as a surrogate endpoint of PDT eﬃcacy.
So, taken as a whole, this study tested several experimental lamps and
assays which can be next implemented in clinical trials.
The ﬁrst step of this work evaluated if PpIX could be photoactivated
by low-irradiance light sources. Although the excitation spectra are
diﬀerent for each light source used in this study, the results presented in
Fig. 2 show that PpIX was eﬀectively activated in each treatment
modality, regardless of the ﬂuence rate. This observation is consistent
with the work performed by Wiegell and co-workers [7], who showed
that there was little accumulation of PpIX during “daylight PDT” in one
of their early clinical trials. The low correlation between PpIX ﬂuorescence and PpIX-weighted light dose observed in our study could
perhaps be due exceeding the minimum light dose that is required to
activate all the PpIX present in the skin.
Since the oxygen available in the tissue is an important key factor
required to ensure PDT outcome, several studies have examined the inﬂuence of ﬂuence light rate on the photochemical oxygen consumption
during PDT. Generally, they have shown a decrease in oxygen depletion
and better treatment responses when a low ﬂuence rate was used
[33,34]. Interestingly, in the current study no signiﬁcant diﬀerences in
relative oxygen saturation and relative blood volume fraction after PDT
were observed for both “daylight PDT” and conventional PDT.

Fig. 5. Quantitative assessments of PDT-induced damage, as shown in
Fig. 3 and 4, display strong linear correlation with each treatment
modality’s respective PpIX-weighted light dose (Table 1).
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investigated further in future studies as a reliable indicator of PDT
outcome.
Taken together, the three bio assays described provide complementary information regarding PDT damage. One of the advantages
of these in vivo biological assays is that comparisons can be made to an
objective biological outcome, even when the light sources might not
have the same eﬀective light dose rate as weighted by the PpIX excitation spectrum. This is quite important given the complexity of adjusting light dose rates weighted through the action spectrum of PpIX,
and how hard it is to accurately match these between diﬀerent light
sources and irradiation conditions. The keratinocyte assay proved the
most practical for superﬁcial, epidermal damage only. STAT3 crosslinking likely presented wider variability due to the nature of the biopsy
containing the full thickness of the skin, and possibly due to the lower
sample numbers taken. This assay and the logistics of it are labor intensive albeit directly sample the biological damage in the tissue.
Finally, the PpIX ﬂuorescence data can complement these biological
assays through its two diﬀerent excitation lasers — the blue laser has a
shorter wavelength and provides more superﬁcial information while the
red excitation laser can penetrate deeper tissues.
5. Conclusions
In summary, since “daylight PDT” could be as eﬀective as a single
ALA-PDT illumination scheme, and there has been exponential growth
in the number of studies using this, there is a need to objectively
compare how well diﬀerent irradiation schemes and light sources aﬀect
PDT outcome. Assessment of photophysical, biochemical, and biological damage can be achieved by the three biometric assays described –
photoactivated bleaching of PpIX, epidermal keratinocyte damage, and
cross-linking of STAT3 protein. Each of these assays gave similar results
qualitatively that followed the trend: fPDT greater than all other
treatment modalities, and low irradiance groups as eﬀective as conventional (single illumination scheme) PDT. This study was somewhat
limited by the variation in PpIX-weighted light doses, but was encouraged by the observation that CFL and sun in particular could still
achieve similar eﬀects to conventional PDT.
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